Farma

bateman
27.08.2018 kl 16:44 7461

Hva tenker dere som kjenner Targovax om det mindre kjente selskapet Ultimovacs som kommer på børs i løpet av høsten?


Safety and tolerability were primary endpoints in all three studies, while
immune response towards any of the UV1 peptides and efficacy were secondary
endpoints.
Three different dose levels of UV1 were investigated in the prostate cancer and
NSCLC studies (100, 300 and 700 µg). In the malignant melanoma study, 300 µg
UV1 was given in combination with ipilimumab. The majority of the UV1 doses
have been given with GM-CSF as an adjuvant treatment.
Data from the three studies showed that UV1 is generally well tolerated. There
were no dose limiting toxicities.
UV1 induced an immune response (hTERT specific T-cells) in 78% of patients
across the three studies (range 67-91%).
When combining UV1 with ipilimumab, a CTLA-4 checkpoint inhibitor, 91% of
malignant melanoma patients developed an immune response. The responses
appeared earlier, required fewer vaccinations, and were stronger and more long
lasting compared to vaccination with UV1 alone. These data are compatible with
a mechanism of action where blocking CTLA-4 checkpoints induce additional
expansion of UV1 specific T cells induced by UV1 vaccination.
The three completed trials show clinical outcomes that Ultimovacs sees as a
strong basis for the next development phase towards registration of UV1;
• Prostate cancer: 73% of patients were alive after 3 years
• Non-small cell lung cancer (NSCLC): Median progression free survival
(mPFS) was reached at 12 months and median overall survival was
reached at 28 months
• Malignant melanoma: Median progression free survival (mPFS) was
reached at 6.5 months and 75% of patients were alive after 2 years


http://ultimovacs.com/cms/wp-content/uploads/2018/07/Ultimovacs-AS-Q118-Report.pdf
Redigert 21.01.2021 kl 08:40

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.